# A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

> **NCT06081829** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Servier** · enrollment: 12 (actual)

## Conditions studied

- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma Metastatic

## Interventions

- **DRUG:** Ivosidenib

## Key facts

- **NCT ID:** NCT06081829
- **Lead sponsor:** Servier
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-10
- **Primary completion:** 2024-10-01
- **Final completion:** 2027-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081829, "A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06081829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*